UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                               ------------------
                                    FORM 6-K

                        REPORT OF FOREIGN PRIVATE ISSUER
                        PURSUANT TO RULE 13a-16 OR 15d-16
                    UNDER THE SECURITIES EXCHANGE ACT OF 1934
                               ------------------
                           For the month of June 2004

                        Commission File Number: 001-31368

                                SANOFI-SYNTHELABO
                 (Translation of registrant's name into English)

                   174, avenue de France, 75013 Paris, FRANCE
                    (Address of principal executive offices)

          Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.

                    Form 20-F  [X]               Form 40-F [ ]

          Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): _____

          Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): _____

          Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.

                    Yes  [ ]                      No  [X]

          If "Yes" marked, indicate below the file number assigned to the
registrant in connection with Rule
12g3-2(b):  82-________


          This  Report  on Form  6-K  shall  be  deemed  to be  incorporated  by
reference   into   Sanofi-Synthelabo's   Registration   Statement  on  Form  F-4
(Registration  No.  333-112314),   as  post-effectively   amended  and  declared
effective on May 13, 2004 by the United States Securities  Exchange  Commission,
and the related prospectus,  dated April 9, 2004, and the prospectus supplement,
dated May 27, 2004,  each filed  pursuant to Rule 424(b) under the United States
Securities  Act of 1933, as amended,  and shall be part thereof from the date on
which this Report is filed, to the extent not superseded by documents or reports
subsequently filed or furnished.



         On June 21, 2004 and June 22, 2004, respectively, Sanofi-Synthelabo
issued the two press releases attached hereto as Exhibit 99.1 and Exhibit 99.2,
each of which is incorporated herein by reference.

                                  EXHIBIT LIST

Exhibit No.                       Description
-----------                       -----------

Exhibit 99.1       Press Release, dated June 21, 2004, announcing the draft
                   structure of SANOFI-AVENTIS Management Committee
Exhibit 99.2       Press Release, dated June 22, 2004, announcing the AMF's
                   decision to postpone the closing date of Sanofi-Synthelabo's
                   Offer for Aventis until July 30, 2004





                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


Dated: June 22, 2004                       SANOFI-SYNTHELABO



                                           By:      /s/  MARIE-HELENE LAIMAY
                                              ----------------------------------

                                              Name:    Marie-Helene Laimay
                                              Title:   Senior Vice President and
                                                       Chief Financial Officer





                                  Exhibit Index

Exhibit No.                       Description
-----------                       -----------

Exhibit 99.1       Press Release, dated June 21, 2004, announcing the draft
                   structure of SANOFI-AVENTIS Management Committee
Exhibit 99.2       Press Release, dated June 22, 2004, announcing the AMF's
                   decision to postpone the closing date of Sanofi-Synthelabo's
                   Offer for Aventis until July 30, 2004